MORRIS PLAINS, N.J., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADCs), today announced the appointment of Robert W. Azelby to the Company’s board of directors. Mr. Azelby is a biotech industry veteran with 28 years of biopharmaceutical experience with a large emphasis on commercialization.

“I am excited to join Immunomedics at an inflection point as the Company is preparing for its first potential commercial launch in its history,” said Mr. Azelby. “I believe that sacituzumab govitecan will become a highly impactful and innovative product across hard-to-treat cancers, and I look forward to working closely with the board to establish Immunomedics as a fully-integrated biopharmaceutical company and a leader in the field of ADCs.”

Mr. Azelby was recently the president and chief executive officer, and a member of the board of directors, of Alder BioPharmaceuticals, Inc., which was acquired by H. Lundbeck A/S in October 2019. Previously, Mr. Azelby served as executive vice president, chief commercial officer of Juno Therapeutics, Inc. where he was responsible for the development and implementation of Juno’s CAR-T commercial strategy and helped guide the organization through rapid growth and ultimately to a $9 billion acquisition by Celgene Corporation. Prior to joining Juno, Mr. Azelby spent 15 years at Amgen Inc. building high-performing commercial teams and leading their U.S. Oncology business.

“We are honored to have Bob join our board at a critical point of our evolution into a commercial organization. Bob will also bring his leadership and experience to shape our commercial strategy in other regions of the world, as we strive to bring what we believe is a critical new therapy to people with mTNBC globally,” said Dr. Behzad Aghazadeh, executive chairman of Immunomedics.

Mr. Azelby currently serves on the board of directors of Clovis Oncology, Inc. and he previously served on the board of directors of Cascadian Therapeutics, Inc. Mr. Azelby holds a B.A. in Economics and Religious Studies from the University of Virginia and an M.B.A. from Harvard Business School.

About Immunomedics

Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer. Immunomedics’ corporate objective is to become a fully-integrated biopharmaceutical company and a leader in the field of antibody-drug conjugates. For additional information on the Company, please visit its website at https://immunomedics.com/. The information on its website does not, however, form a part of this press release.